Darzalex gains EU approval for new frontline combination treatment

Janssen has announced EU approvalĀ of Darzalex (daratumumab) for use alongside Takeda’sĀ Velcade (bortezomib), melphalan and prednisone (VMP) for newly diagnosed myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant (ASCT). The approval is based on results of the ALCYONE clinical trial which showed that adding Darzalex to VMP reduces the risk of…

Details